Strategies to Prevent Manufacture and Distribution of Substandard Medications

Michael  Esposito
Instructor: Michael  Esposito
Date: Friday December 13, 2024
Time:

10:00 AM PST | 01:00 PM EST

Duration: 90 Minutes
Webinar Id: 23297

Price Details

Live Webinar
$150. One Attendee
$290. Unlimited Attendees
Recorded Webinar
$190. One Attendee
$390. Unlimited Attendees
Combo Offers   (Live + Recorded)
$289 $340   One Attendee
$599 $680   Unlimited Attendees

Unlimited Attendees: Any number of participants

Recorded Version: Unlimited viewing for 6 months (Access information will be emailed 24 hours after the completion of live webinar)

Overview:

Substandard product can exist even if the product itself is manufactured according to quality standards. Harm to patients and damage to a company's reputation are the two most obvious consequences of substandard product.

Yet, many companies pay too little attention to these problems, preferring short-term gain over long-term reputation and profitability. Within companies, it is common to hear the argument that quality is a cost center and does not directly contribute to the company's profits. While the quality function is obviously not the same as sales and marketing, prevention of losses due to quality issues (e.g., product recalls) or remediation (e.g., addressing lawsuits or FDA enforcement actions) affects the bottom line every bit as much as sales. In this webinar we provide you with best practices that have been proven effective and equip you with the means to advocate for these ideas within your organization.

Why you should Attend:

If a legitimate product is not manufactured according to quality standards or becomes degraded as it travels through its supply chain, it can be ineffective at best or deadly at worst. Examples of potential dangers that can occur include temperature excursions, inappropriate use, and unsafe ingredients inadvertently added to the product. In terms of effect, substandard pharmaceutical product is a worldwide issue on a par with counterfeiting.

Areas Covered in the Session:

  • The problem
    • Poisons
    • Temperature excursions
    • Risks to patients
    • Risks to companies
  • Solutions
    • Maintain a robust quality system
      • Supplier quality
      • Product testing
      • Monitoring temperature
    • Join industry and governmental efforts to improve product quality worldwide
      • Current initiatives
      • Benefits to Pharma companies
    • Explore new technologies to bolster product integrity
      • Blockchain
      • Portable testing devices
    • Make a hardheaded assessment of risk and reward when assessing cost reduction initiatives
      • Identify most vulnerable areas
      • Cost-benefit considerations
  • Review of learning objectives

Who Will Benefit:

  • Pharmaceutical Industry
  • Supply Chain
  • Quality Assurance
  • Packaging and Labeling
  • Manufacturing
  • Warehousing and Distribution

Speaker Profile
Michael Esposito has over 30 years experience in the pharmaceutical industry and 17 years experience in GMP training and document management. He has worked for Wyeth Pharmaceuticals, Pfizer and Johnson & Johnson's McNeil Consumer Healthcare Division in a variety of areas including Packaging, project administration, Quality Assurance, Government Contracts, translations, systems training, and international operations. He collaborated in the development and implementation of the training portion of the Consent Decree workplan for McNeil and revised their introductory GMP course. He is a member of the training organizations GMP Training Educators Association and Association for GXP Excellence (AGXPE) and is fully fluent in Spanish. His areas of interest include systems training, training effectiveness, post-training user support, process improvement, and sustainable packaging.

Sign Up for Our Newsletter